Evercyte GmbH

What Evercyte GmbH does

Evercyte GmbH is a Vienna-based biotechnology company founded in 2011 that develops continuously proliferating human primary cell lines through proprietary hTERT-based telomerization, addressing a core constraint in cell biology where primary cells typically enter senescence after limited division cycles. The company translates this capability into a catalog of telomerized mesenchymal stem cells (from sources including perinatal and endometrial tissue), trophoblasts, endothelial cells, and fibroblasts, alongside extracellular vesicles (EVs) derived from those cell lines, EV-producing cell factories, and specialized cell culture media.

The business model is dual: direct product sales of cells and reagents (cells priced at approximately 1,200 EUR per vial), and contract research services covering cell line development, drug screening assays, EV characterization (aligned with MISEV2023), and gene editing. Customers are segmented by intended use, with academic users receiving unlimited-use licenses and for-profit commercial users requiring paid licensing arrangements. Named commercial customers include Apellis Pharmaceuticals and Cytonus Therapeutics; additional revenue is generated through a network of distributors covering more than 20 countries and through academic and clinical research supply.

Evercyte operates within an Austrian life-sciences cluster anchored by the Vienna BioCenter, BOKU, the Medical University of Vienna, and the Ludwig Boltzmann Institute for Traumatology. Sister companies TAmiRNA GmbH and Phoenestra GmbH indicate a broader founder-controlled group structure. Quality and compliance positioning rests on documented ethical approvals, GCCP-aligned manufacturing, and MISEV2023-compatible EV characterization, supporting adoption in regulated customer segments.

Name

Evercyte GmbH

Legal name

Evercyte GmbH

Website

https://evercyte.com

Company type

Private

Founded year

2011

Operating status

Operating

Headcount range

1–10 employees

Short description

Evercyte GmbH is a Vienna-based biotechnology company that produces telomerized human primary cell lines and extracellular vesicle products using proprietary hTERT immortalization technology, serving pharmaceutical, biotech, and academic research customers globally through direct sales, licensing, and a distributor network.

Ownership category

akta.pro rank

Product category

Biotechnology reagents and cell-based research services

NAICS

Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAAABAL

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAABAH

Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

SECONDARYHLAAABAK

Cell Therapy Quality, Analytics & Release Testing (potency, sterility, comparability)

Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

• Telomerized human cell lines
• Extracellular vesicle production
• Cell line licensing
• Preclinical drug screening
• Contract research services

Headquarters

HQ city

Breitenfurt Bei Wien

HQ country

Austria

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Cell Line Licensing: Licensing out telomerized cell lines to customers. License conditions depend on customer type (nonprofit vs for-profit) and intended use. Academic/nonprofit organizations receive unlimited period licenses for R&D purposes. For-profit organizations pay annual license fees after initial testing phase flat fee.
2. Contract Research Services: Fee-for-service offerings including cell line development, bioassay performance, toxicology testing, and production/characterization of extracellular vesicles. Billed as fee-for-service with interactive collaboration.
3. Ready-to-Use Extracellular Vesicles: Off-the-shelf EVs from mesenchymal stromal cells sold as consumables. Additional vials of cell lines priced at 1200 EUR per vial.
4. Cell Culture Media: Proprietary cell culture media products (ColoUp, PodoUp, ProxUp, MyoUp, TrophoUp) sold as consumables for growth of specific cell types.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Evercyte develops, licenses and supplies continuously growing human telomerized cell lines (created via hTERT expression) that retain primary cell functions, along with off-the-shelf extracellular vesicles, MSC-based EV cell factories and proprietary cell culture media. The company complements these products with fee-for-service contract research including custom cell line development, drug/substance screening, EV enrichment and potency testing under MISEV2023, and CRISPR-based gene editing studies.

Product overview

Evercyte GmbH is a biotechnology company offering a portfolio of telomerized human cell lines and extracellular vesicle (EV) products, complemented by contract research services. The core offering consists of human telomerized cell lines (introduced via hTERT expression) that maintain primary cell functions while enabling continuous expansion. These cells serve dual purposes: as advanced in vitro test systems for preclinical drug testing and as cell factories for scalable EV production. The product portfolio includes: (1) catalogued telomerized cell lines by tissue and cell type, (2) off-the-shelf extracellular vesicles from various MSC sources, (3) EV cell factory lines for customer-controlled EV production, and (4) specialized cell culture media. Service offerings encompass custom cell line development, drug/substance screening, EV characterization and potency testing, and gene editing studies.

Differentiator

Problem solved

Functional benefit

Products and services

• Telomerized Human Cell Lines Continuously growing human cell lines with extended proliferative capacity via hTERT expression that maintain cell type-specific characteristics and functions, available licensed for in vitro testing, EV production, and biomedical research.
• Off-the-shelf Extracellular Vesicles Pre-isolated, ready-to-use extracellular vesicles (EVs) from mesenchymal stromal cells of various tissue origins (adipose, bone marrow, endometrium, placenta) sold as consumables for research applications.
• EV Cell Factories Telomerized MSC lines including EN-MSC/TERT352-B, WJ-MSC/TERT273 and placental MSC lines that customers can use as scalable, standardized cell factories for in-house EV production.
• Cell Culture Media Specialized cell culture media formulations including ColoUp and ColoUp2 (colon cells), PodoUp3 (podocytes), ProxUp2 and ProxUp3 (renal cells), MyoUp and MyoUp2 (muscle cells), and TrophoUp (trophoblasts) sold as consumables.
• Cell Line Development Services Custom cell line development services including primary cell culture, lifespan extension via telomerization, cell line characterization and preparation of assay-ready cells for client-specific projects.
• Drug Screening and Substance Testing Services Substance testing services including cytotoxicity/proliferation assays, cytokine targeting studies, senolytic and senomorphic activity assays, anti-fibrotic activity testing, neo-angiogenic potential assessment, and wound healing activity evaluation performed on Evercyte's human telomerized cell models.
• EV Enrichment, Characterization and Potency Testing Services Lab-scale EV production, recombinant exosome engineering, EV marker protein analysis, cryo-EM characterization, RNA cargo analysis and functional potency testing performed in compliance with MISEV2023 criteria for academic and industry clients.
• Gene Editing Studies Services Gene editing studies including knock-in/knock-out modifications, reporter cell line development, CRISPR/Cas9 engineering and functional testing of gene-modified cells for client research projects.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

15 partnerships are on record, tiered core and minor.

• TAmiRNA GmbHcoreStrategic or Co-development PartnerSister company co-founded by Regina and Johannes Grillari. TAmiRNA focuses on microRNA analysis and diagnostics. Companies collaborate on EV characterization and share booth at ISEV 2025 showcasing EV*scale platform.
• Phoenestra GmbHcoreStrategic or Co-development PartnerSister company co-founded by founders. Phoenestra focuses on drug delivery and pharmaceutical development. Companies share expertise and collaborate on EV projects.
• AIM BiotechcoreStrategic or Co-development PartnerCollaboration to develop innovative 3D assay kits. Evercyte’s HUVEC/TERT2 and LF/TERT309 cells incorporated into AIM Biotech’s angiogenesis and microvascular network microfluidic kits.
• ACIB (Austrian Centre of Industrial Biotechnology)minorStrategic or Co-development PartnerResearch partner in CD81 engineering platform for recombinant EVs. Collaboration on extracellular vesicle targeting technologies.
• Ludwig Boltzmann Institute for Traumatology (LBI Trauma)minorStrategic or Co-development PartnerJohannes Grillari serves as director since 2019. Research collaboration on EV research and trauma treatment applications.
• University of Natural Resources and Life Sciences Vienna (BOKU)minorStrategic or Co-development PartnerAcademic partner. Regina Grillari received venia docendi from BOKU in 2008. Collaboration on CD81 EV engineering project.
• Summit PharmacoreChannel Partner/ Reseller/ DistributorExclusive distributor for Japan and Taiwan markets. Distributes Evercyte cell lines, EVs, and media products in these regions.
• Voden MedicalcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Italy. Markets cell lines and related products to Italian research and pharmaceutical community.
• InterlabcoreChannel Partner/ Reseller/ DistributorExclusive distributor for Taiwan. Part of distribution network for Evercyte products in Asian markets.
• CliniSciencescoreChannel Partner/ Reseller/ DistributorDistributor covering UK, Ireland, France, Spain, Portugal, Switzerland, Austria, US, Morocco, Germany, Belgium, Netherlands. One of the primary European/American distributors.
• BioMedia/SPDcoreChannel Partner/ Reseller/ DistributorDistributor for Singapore market. Part of Asia-Pacific distribution network.
• BioScotia TechnologiesminorChannel Partner/ Reseller/ DistributorDistributor for Canada. Expanding North American market coverage.
• MDimuneminorStrategic or Co-development PartnerPartnership for developing tumor-targeting EVs. Collaboration on targeted extracellular vesicle therapeutics.
• Vienna BioCenter (VBC)minorStrategic or Co-development PartnerInnovation campus membership providing access to biotech ecosystem, shared facilities, and networking opportunities in Vienna.
• Medical University of ViennaminorStrategic or Co-development PartnerAcademic partner for research collaborations in extracellular vesicles and cell biology.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• CellGenix GmbH: German manufacturer of GMP-grade raw materials and reagents for cell and gene therapy. Directly comparable as a cell-therapy enabling technologies supplier serving academic translational centers and commercial therapy developers.
• System Biosciences (SBI): US-based supplier of exosome/EV research tools including purified EVs, EV engineering platforms, and exosome isolation kits. Direct competitor in the research-grade extracellular vesicle product category.
• Applied Biological Materials (abm): Canadian supplier of cell lines, primary cells, viral vectors, and cell biology reagents for research and biotech applications. Comparable product/catalog model targeting academic and pharma researchers with specialty cell-based tools.
• iXCells Biotechnologies: US-based provider of primary cells, iPSC-derived cells, and cell-based assay services for drug discovery. Comparable business model combining catalog cell products with custom research services for pharma/biotech clients.
• PromoCell GmbH: German-based provider of human primary cells and telomerized cell lines for research and biotech applications. Direct competitor to Evercyte in specialty human cell models with overlapping academic and pharma customers in DACH and broader Europe.
• Innoprot: Spanish provider of primary cells, cell lines, and cell-based assay services for drug discovery research. Comparable boutique-scale cell line supplier serving European pharma and academic customers.

Broad incumbents

• ATCC: Global nonprofit biological materials resource providing cell lines, reagents, and standards. Operates as a broad incumbent cell line catalog across all tissue types and is a default reference supplier for academic and pharma labs.
• Lonza Group: Global CDMO and cell therapy manufacturing leader offering cell engineering services, cell line development, and GMP manufacturing for therapeutic developers. A much larger incumbent that overlaps with Evercyte's cell engineering and EV manufacturing technical domains.

Emerging players

• ReachBio LLC: US supplier of primary cells and cell-based assay services for hematology and drug discovery research. Comparable boutique provider offering catalog cells plus contract assay services to pharma/biotech.
• RoosterBio Inc. US-based MSC and extracellular vesicle platform company offering scalable cell banks and EV production media. Strongly comparable as an MSC-derived EV production specialist competing in the same therapeutic EV cell factory space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/evercyte

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evercyte GmbH